Neurocrine Biosciences Inc. NBIX
Super Investor & Insider
1
Fondi che lo detengono
#729
Rank consenso
1.4%
% dei portafogli
$719.4M
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Dodge & Cox · Dodge & Cox | 0.4% | Reduce 0.85% | 5,461,037 | $719.4M |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Neurocrine Biosciences Inc. is a neuroscience-focused biopharmaceutical company specializing in the discovery, development, and commercialization of treatments for neurological, neuropsychiatric, endocrine, and metabolic disorders. Its flagship product, INGREZZA (valbenazine), a VMAT2 inhibitor, addresses tardive dyski…
SectorHealthcare
ExchangeNASDAQ
IndustryDrug Manufacturers - Specialty & Generic
CountryUnited States
Employees2,000
TickerNBIX
Statistics
Market Cap$16.02B
Revenue (TTM)$2.86B
Net Income$478.6M
Net Margin16.7%
EPS$4.67
P/E24.79
P/S5.21
P/B4.75
EV/EBITDA18.49
ROE22.5%
Dividend Yield—
Price$159.25
Data: Twelve Data · Revenue = mcap / P/S